2024
Endothelial HIFα-PDGF-B to smooth muscle Beclin1 signaling sustains pathological muscularization in pulmonary hypertension
Saddouk F, Kuzemczak A, Saito J, Greif D. Endothelial HIFα-PDGF-B to smooth muscle Beclin1 signaling sustains pathological muscularization in pulmonary hypertension. JCI Insight 2024, 9: e162449. PMID: 38652543, PMCID: PMC11141934, DOI: 10.1172/jci.insight.162449.Peer-Reviewed Original ResearchSmooth muscle cellsArteriole smooth muscle cellsPulmonary hypertensionPlatelet-derived growth factor-BDistal muscularizationSugen 5416Endothelial cellsHuman idiopathic pulmonary arterial hypertensionHypoxia-induced pulmonary vascular remodelingPulmonary artery smooth muscle cellsIdiopathic pulmonary arterial hypertensionHypoxia-inducible factor (HIF)-1aArtery smooth muscle cellsDistal pulmonary arteriolesPulmonary arterial hypertensionPulmonary vascular remodelingDeletion of Hif1aLung endothelial cellsGrowth factor BEC-specific deletionPulmonary arteriolesArterial hypertensionLung lysatesMuscle cellsVascular remodeling
2023
Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials
Blette B, Moutchia J, Al-Naamani N, Ventetuolo C, Cheng C, Appleby D, Urbanowicz R, Fritz J, Mazurek J, Li F, Kawut S, Harhay M. Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials. The Lancet Respiratory Medicine 2023, 11: 873-882. PMID: 37230098, PMCID: PMC10592525, DOI: 10.1016/s2213-2600(23)00155-8.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionPulmonary arterial hypertension trialsWorsening pulmonary arterial hypertensionFood and Drug AdministrationLow-risk statusClinical worseningLong-term outcomesRisk scoreArterial hypertensionPAH associated with connective tissue diseaseIdiopathic pulmonary arterial hypertensionPulmonary arterial hypertension treatmentSurrogate outcomesObservational study of outcomesLong-term follow-upDiscontinuation of study treatmentWHO functional classUS Food and Drug AdministrationMeta-analysisMeta-analysis of RCTsAll-cause deathConnective tissue diseaseEffects of therapyPredictive of outcomeTreatment effectsA Case of Fulminant Right Heart Failure Owing to Tumoral Pulmonary Hypertension
Wang K, Verma A, Fish K, Hu J, Miller P, Morrow J, Singh I, Young L. A Case of Fulminant Right Heart Failure Owing to Tumoral Pulmonary Hypertension. JACC Case Reports 2023, 10: 101715. PMID: 36974052, PMCID: PMC10039392, DOI: 10.1016/j.jaccas.2022.101715.Peer-Reviewed Case Reports and Technical Notes
2021
Phosphoproteomic analysis of lung tissue from patients with pulmonary arterial hypertension
Sitapara R, Lam TT, Gandjeva A, Tuder RM, Zisman LS. Phosphoproteomic analysis of lung tissue from patients with pulmonary arterial hypertension. Pulmonary Circulation 2021, 11: 1-15. PMID: 34966541, PMCID: PMC8711668, DOI: 10.1177/20458940211031109.Peer-Reviewed Original ResearchCyclin-dependent kinase 1Pulmonary arterial hypertensionProtein kinasePhosphoproteomic analysisIdiopathic PAHKinase 1Zinc finger transcription factorLung tissueFinger transcription factorCGMP-dependent protein kinase 1Casein kinase 2Regulation of BclMass spectrometry-based analysisProtein kinase 1Arterial hypertensionImmune regulationImportant regulatory roleIdiopathic pulmonary arterial hypertensionRhoGTPase signalingGSK3 alphaKinase networkPhosphorylation assaysTranscription factorsBioinformatics analysisGSK3 betaImpact of right ventricular work and pulmonary arterial compliance on peak exercise oxygen uptake in idiopathic pulmonary arterial hypertension
Messina CMS, Ferreira EVM, Singh I, Fonseca AXC, Ramos RP, Nery LE, Systrom DM, Oliveira RKF, Ota-Arakaki JS. Impact of right ventricular work and pulmonary arterial compliance on peak exercise oxygen uptake in idiopathic pulmonary arterial hypertension. International Journal Of Cardiology 2021, 331: 230-235. PMID: 33545265, DOI: 10.1016/j.ijcard.2021.01.027.Peer-Reviewed Original ResearchConceptsRV stroke work indexPulmonary arterial hypertensionRight heart catheterizationExercise right heart catheterizationIdiopathic pulmonary arterial hypertensionIdiopathic PAHCardiac outputPA complianceArterial hypertensionRight ventricularDynes/s/Mean pulmonary arterial pressurePeak exercise oxygen uptakePeak stroke volume indexPA wedge pressurePeak cardiac indexPulmonary vascular resistanceStroke volume indexStroke work indexCardiopulmonary exercise testingPulmonary arterial pressurePulmonary arterial complianceRight ventricular workAge-adjusted multivariate modelExercise oxygen uptake
2016
The emerging role of microRNAs in hypoxia-induced pulmonary hypertension
Mohsenin V. The emerging role of microRNAs in hypoxia-induced pulmonary hypertension. Sleep And Breathing 2016, 20: 1059-1067. PMID: 27154628, DOI: 10.1007/s11325-016-1351-y.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionHypoxia-induced pulmonary hypertensionPulmonary hypertensionArterial hypertensionHeart failureRole of microRNAsMechanism of PHPulmonary arterial blood pressurePulmonary arterial smooth muscle cellsDevelopment of PHIdiopathic pulmonary arterial hypertensionChronic obstructive lung diseasePathogenesis of PHArterial smooth muscle cellsRight heart failureRight ventricular dysfunctionPoor prognostic signArterial blood pressureCongestive heart failureObstructive lung diseaseSleep-disordered breathingSetting of hypoxiaAberrant vascular remodelingQuality of lifeSmooth muscle cells
2015
Role of Vasodilator Testing in Pulmonary Hypertension
Sharma A, Obiagwu C, Mezue K, Garg A, Mukherjee D, Haythe J, Shetty V, Einstein A. Role of Vasodilator Testing in Pulmonary Hypertension. Progress In Cardiovascular Diseases 2015, 58: 425-433. PMID: 26434988, DOI: 10.1016/j.pcad.2015.09.006.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionCalcium channel blockersVasodilator testingPulmonary arteryIdiopathic pulmonary arterial hypertensionNormalization of pulmonary hemodynamicsAcute vasodilator testingRight heart catheterizationInhaled Nitric OxideMean pulmonary arteryInhaled iloprostIntravenous epoprostenolHeart catheterizationPulmonary hypertensionVasoreactivity testingIntravenous adenosineArterial hypertensionChannel blockersPulmonary hemodynamicsNear normalizationStandard agentsPatientsNitric oxideHypertensionVasodilation
2010
Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension
Rajkumar R, Konishi K, Richards TJ, Ishizawar DC, Wiechert AC, Kaminski N, Ahmad F. Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension. AJP Heart And Circulatory Physiology 2010, 298: h1235-h1248. PMID: 20081107, PMCID: PMC2853417, DOI: 10.1152/ajpheart.00254.2009.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionIdiopathic pulmonary fibrosisPathogenesis of PAHIdiopathic pulmonary arterial hypertensionPulmonary hypertensionArterial hypertensionRegulation of actinThrombospondin type 1 motif 9Pulmonary arteriolar remodelingSecondary pulmonary hypertensionCoagulation factor II receptorDistinct pathophysiological mechanismsLife-threatening conditionDistinct gene expression signaturesEstrogen receptor 1Nuclear receptor coactivator 2RNA expression profilesPurinergic receptor P2YGenomewide microarray analysisPlatelet factor 4RNA expression profilingHigh expression levelsOncogene homolog 1Gene expression signaturesProtein ubiquitination
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply